



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dahlberg *et al.*

Serial No.: 09/941/193

Group No.:

Filed: 08/28/01

Examiner:

Entitled: Systems For the Detection of Target Sequences

**RESPONSE TO THE NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES MAILED
May 2, 2002, AND PRELIMINARY AMENDMENT BY
SUBSTITUTE SPECIFICATION UNDER 37 C.F.R.
§1.121(3), AND SUBSTITUTE DRAWINGS UNDER 37
C.F.R. §1.121(d)**

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Dated: 7-2-02

Mary Ellen Waite
Mary Ellen Waite

Sir or Madam:

This is responsive to a "NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES," mailed on May 2, 2002 and setting a two-month period for response which ends on July 2, 2002.

Prior to examination of the instant application, please amend the application by replacing the specification pursuant to 37 C.F.R. § 1.121(b)(3) and 37 C.F.R. § 1.125(b). Applicants enclose the following herewith:

- (A) A substitute specification in clean form without markings as to amended material, and having paragraphs individually numbered pursuant to 37 C.F.R. § 1.125(c) (Tab 1). The clean substitute specification begins on page 1 and ends on page 303. The clean substitute specification includes no new matter; and
- (B) A marked-up copy of the substitute specification (Tab 2) pursuant to 37 C.F.R. § 1.125(b)(2), showing the matter that was added and deleted from the specification. Added matter is underlined, and deleted matter is bracketed.


In this substitute specification, brackets other than those used to indicate deletions have been replaced by parentheses. Trademarks have been capitalized where they appear.

Drawings 6, 12A, 13A, 14-16, 19-21 and 23 show sequences and have been amended to add sequence identifiers. Pursuant to 37 C.F.R. § 1.121(d), a separate paper for each drawing showing the proposed changes in red is submitted herewith (see Tab 3). For Examiner's convenience, drawings having the changes in black are also included (see Tab 4). The substitute specification includes amendments to add references to these sequence identifiers.

The Examiner has requested that a Sequence Listing pursuant to 37 C.F.R. §§ 1.821(a)(1) and (a)(2) be provided as the one filed February 2, 2002 had formatting problems throughout. Submitted herewith is a substitute paper copy that begins on page 1 and ends on page 96, and a substitute computer readable form of a "Sequence Listing." The contents of the paper and computer readable copies are the same and include no new matter.

Respectfully submitted,

Dated: July 2, 2002


David A. Casimir
Registration No. 42,395

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500